Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03110549 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers
A Phase 1 study, sponsored by TaiMed Biologics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT03110549 is a Phase 1 study that was terminated before completion, run by TaiMed Biologics. The registered enrollment target is 9 participants.
The verdict
NCT03110549, a Phase 1 study, was terminated before completion, sponsored by TaiMed Biologics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The study is a Phase 1, randomized, double-blinded, placebo-controlled, sequential single dose escalation safety, tolerability and pharmacokinetic study of subcutaneous and intramuscular TMB-607 administered to HIV-negative volunteers.
Interventions
- DRUG Placebo
- DRUG TMB-607
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-11-21 |
| Est. Completion | 2019-07-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03110549
The ClinicalTrials.gov registry entry for NCT03110549 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TaiMed Biologics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03110549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03110549 about?
NCT03110549 is a clinical study titled "Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers". The study is a Phase 1, randomized, double-blinded, placebo-controlled, sequential single dose escalation safety, tolerability and pharmacokinetic study of subcutaneous and intramuscular TMB-607 administered to HIV-negative volunteers.
What is the current status of trial NCT03110549?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2016-11-21. Estimated completion is 2019-07-22.
What interventions are being tested in trial NCT03110549?
The interventions under investigation include: Placebo (DRUG), TMB-607 (DRUG).
Who is sponsoring clinical trial NCT03110549?
This trial is sponsored by TaiMed Biologics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.